- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03892096
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Most anticancer drugs are effective only in subgroups of patients, and our current understanding of tumor biology does not allow us to predict accurately which patient will benefit from a specific therapeutic regimen. The definitive proof of the effectiveness of a therapy is improvement in clinical symptoms and survival. Imaging is generally used to assess therapeutic effects earlier and more objectively. Current response assessment is based primarily on changes in tumor size as measured by CT or other anatomic imaging modalities.
Cadex Genomics has developed an analytically validated cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay that utilizes standard qPCR platforms for processing, this test can reliably obtain results from small blood volumes and possesses exceptionally high analytical sensitivity of circulating cfDNA.
The purpose of this study is to accrue samples for the further development and clinical validation of a blood-based cell-free cfDNA qPCR assay as a potential biomarker for early non-response to therapy in stage IV non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BC).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H3H 2R9
- McGill University
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- CARTI Cancer Center
-
-
California
-
Sunnyvale, California, United States, 94086
- Sutter Health - Palo Alto Medical Foundation
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Centers
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- IACT Health
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- University Medical Center
-
New Orleans, Louisiana, United States, 70119
- Southeast Louisiana Veterans Health Care System
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Center
-
-
New York
-
Port Jefferson Station, New York, United States, 11776
- National Translational Research Group LLC
-
-
North Carolina
-
Cary, North Carolina, United States, 27518
- Waverly Hematology Oncology
-
Hendersonville, North Carolina, United States, 28732
- Advent Health
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Greenville Health System - Prisma Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Age ≥ 18 years.
Documented stage IV NSCLC, SCLC, BC or CRC (can be new diagnosis, persistent or recurrent disease):
BC patients who meet the following criteria:
ER+/HER2- and has failed hormone therapy within the last two years, or ER+/HER2+ or, ER-/HER+ or, HER2-/ER-/PR- (TNBC), and Has ≥ 1 measurable non- bone lesion as measured per RECIST or, If bone only disease, has two or more measurable (> 1 cm by RECIST) predominantly lytic bone lesions
Planned initiation of new systemic first- or second-line treatment or subsequent therapies with chemotherapy, immunotherapy, targeted therapy or combination thereof. Or continuation of the current line of therapy after RECIST/iRECIST evaluation which coincides with end of the cycle of therapy and prior to initiation of the next cycle of therapy.
Imaging to determine RECIST and/or iRECIST criteria:
If baseline blood draw is planned prior to first cycle of a line (1st, 2nd, 3rd etc) of therapy, measurable disease with CT or MRI or PET/CT monitoring should be completed within 4 weeks prior to baseline blood draw.
If baseline test is performed at the completion of a cycle of therapy, CT or MRI or PET/CT monitoring should be completed to coincide with end of cycle of therapy and prior to baseline blood draw.
Planned CT or MRI or PET/CT monitoring for treatment response completed within 8-12 weeks of start of treatment.
Willing and able to donate up to 30mL of blood at each blood draw. Willing and able to provide informed consent.
Exclusion Criteria:
Diagnosis of a secondary malignancy that is not in complete remission. Imaging to determine RECIST and/or iRECIST criteria is not planned or available.
CT or MRI or PET/CT monitoring for treatment response is not planned within 8-12 weeks.
Presence of active autoimmune disease which is under active treatment. DVT, PE, sepsis, or has recovered from any other serious illness within the prior 2 weeks of the baseline blood draw. (Note: Patients who have recovered from similar conditions more than 2 weeks prior to the baseline blood draw would be eligible for the study) If initiating a new line of therapy, patient has received any doses of the new block of therapy before the first designated blood draw.
If continuing current line of therapy after CT, MRI or PET/CT monitoring, patient has received subsequent cycle of therapy before the first designated blood draw.
Performance status ECOG ≥3. Evidence of acute renal failure as determined by current clinical guidelines. NSCLC, SCLC or CRC patients beyond 9 months of the initiation of therapy, on 1st line immunotherapy alone, or combination immunotherapy and chemotherapy regimens. (Note: patients on subsequent lines of therapy (2nd,3rd line etc.) would be eligible at any time point including prior to the 9 months vs those patients on 1st line therapy)..
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer
A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled.
It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
|
Up to 30mL of blood via venipuncture
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DNA Integrity Index as a predictor of progressive disease in a cohort of metastatic patients (250 Lung Cancer (NSCLC, SCLC), 250 CRC and 250 BC patients as compared to standard RECIST/iRECIST criteria.
Time Frame: Six months to accrue patient for initial development
|
A total of 750 subjects (250 stage IV Lung Cancer, IV 250 CRC and IV BC) will be enrolled consecutively into the study.
Blood specimens will be collected at the initiation of therapy and 12 to 16 days after the initiation of therapy.
A course of therapy is defined as chemotherapy, immunotherapy or oral therapy.
Standard baseline RECIST or iRECIST will be recorded before the initiation therapy and again at 9-12 weeks.
For those patients who are receiving single agent regimen consisting of immunotherapy alone there will be an additional blood draw prior to administration of the second course of therapy.
The Integrity Index will be evaluated for predicting early non-response to therapy as compared to standard RECIST/iRECIST results.
|
Six months to accrue patient for initial development
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Christer Svedman, M.D. Ph.D., Cadex Genomics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CADEX-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on Blood-based cell-free cfDNA qPCR assay
-
Vastra Gotaland RegionKarolinska University Hospital; Lund University HospitalCompletedHeart Transplant RejectionSweden
-
Universitaire Ziekenhuizen KU LeuvenRecruitingNeurodevelopmental Disorders | Biomarkers | Congenital Heart Disease | Electroencephalography | Near-Infrared SpectroscopyBelgium
-
NYU Langone HealthViracor EurofinsNot yet recruiting
-
Meir Medical CenterCompleted
-
Singlera Genomics Inc.Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRecruiting
-
Universidad Autónoma de BucaramangaInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS) and other collaboratorsUnknown
-
Seoul National University HospitalGENECAST Co., Ltd.RecruitingPancreatic CancerKorea, Republic of
-
University of California, San FranciscoRecruiting
-
Hospices Civils de LyonCompletedAutoimmune Encephalitis | Paraneoplastic Neurological SyndromeFrance
-
Seoul National University HospitalDXOME CO., LTD.RecruitingPancreatic Cancer | Cholangiocarcinoma | Gallbladder CancerKorea, Republic of